- Home
- EBMT vs ANVS Comparison
EBMT vs ANVS Comparison
Compare EBMT & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBMT | ANVS |
|---|---|---|
| Founded | 1922 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.7M | 69.1M |
| IPO Year | 2009 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EBMT | ANVS |
|---|---|---|
| Price | $21.75 | $1.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $24.00 | $13.50 |
| AVG Volume (30 Days) | 36.3K | ★ 923.2K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 53.23 | 39.39 |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $42.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.11 | $1.54 |
| 52 Week High | $23.95 | $5.50 |
Technical Indicators
Market Signals| Indicator | EBMT | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 43.00 |
| Support Level | $21.59 | $1.86 |
| Resistance Level | $22.88 | $2.57 |
| Average True Range (ATR) | 0.65 | 0.16 |
| MACD | -0.14 | -0.01 |
| Stochastic Oscillator | 9.14 | 13.92 |
Price Performance
Historical ComparisonAbout EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.